

Hong Kong Exchanges and Clearing Limited and the Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

**SUPPLEMENTAL ANNOUNCEMENT
IN RELATION TO
ANNUAL RESULTS ANNOUNCEMENT DATED 20 DECEMBER 2024**

Reference is made to the annual results announcement for the year ended 30 June 2024 of Wai Chun Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 20 December 2024 (the “**Result Announcement**”) and the supplemental announcement of the Company dated 13 January 2025 (the “**Supplemental Announcement**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Result Announcement and the Supplemental Announcement.

In addition to the information disclosed in the Result Announcement and the Supplemental Announcement, the Company would like to provide the following information in relation to the remedial actions mentioned in the Supplemental Announcement.

Remedial Actions		Expected timeline
1	The Company is actively recruiting (i) a competent personnel to take up the position of chief financial officer of the Company and (ii) additional accountants or accounting staff to ensure that there is sufficient manpower to engage in the monthly financial reporting and annual audit procedures.	The Company expects to hire suitable employees on or before 30 June 2025.

Remedial Actions		Expected timeline
2	The chief financial officer will prepare the interim results/annual results timetable which specifies (i) the commencement of audit work; (ii) the circulation of the first draft of audited financial statement of the Group to the Board; (iii) the proposed date of interim results/annual results result announcement; and (iv) the proposed date of board meeting. The proposed timetable will be agreed with the auditor in advance and submitted to the executive Director(s) of the Company for review and approval.	The timetable of interim result and annual result will be finalized by the end of January 2025 and July 2025, respectively.
3	The Company will plan and commence the preparation of audit work in advance before the year end.	The preparation of annual audit is expected to commence in June 2025.

The Company will make further announcement on the implementation of the above-mentioned remedial actions as and when appropriate.

By Order of the Board
Wai Chun Bio-Technology Limited
LAM Ka Chun
Executive Director

Hong Kong, 14 January 2025

As at the date of this announcement, the Board comprises:

Executive Director:
LAM Ka Chun

Independent Non-executive Directors:
WAN Bo
HE Tao
KUNG Ying Tung